HOLLISTERSTIER SEES CONTRACT IN PRISM

A A

HollisterStier has signed a deal to develop a process for compounding and fill/finishing PM101, Prism's acute care cardiovascular drug. Under the deal, HollisterStier will produce PM101 registration material for clinical trials and is supporting Prism'filing of a new drug application (NDA).

Big News (http://feeds.bignewsnetwork.com/redir.php?jid=61af44539a63ab84&cat=6dcd932030878143)